Evaluation of a labdane diterpene forskolin isolated from *Solena amplexicaulis* (Lam.) Gandhi (Cucurbitaceae) revealed promising antidiabetic and antihyperlipidemic pharmacological properties

Arjunan Venkatachalapathi,⇑ Krishnaswamy Thenmozhi, Krishnamoorthy Karthika, Mohammad Ajmal Ali,⇑ Subramaniyam Paulsamy, Fahad AlHemaid, Mohamed Soliman Elshikh

Department of Botany, Kongunadu Arts and Science College, Coimbatore 641029, Tamil Nadu, India

Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia

**A R T I C L E  I N F O**

Article history:
Received 14 July 2018
Revised 9 August 2018
Accepted 12 August 2018
Available online 12 August 2018

**Keywords:**
*Solena amplexicaulis*
Cucurbitaceae
Forskolin
Antidiabetic
Antihyperlipidemic
Antioxidant

**A B S T R A C T**

*Solena amplexicaulis* (Lam.) Gandhi (Family Cucurbitaceae) is one of the important plant species used by the Irula tribes of Walayar valley of southern Western Ghats, India for the management of diabetes. To confirm the antidiabetic property of *S. amplexicaulis*, the present study was addressed using crude methanolic leaf extract of *S. amplexicaulis* (MeOHSa) and its isolated compound, Forskolin against streptozotocin (STZ) induced diabetic rats. The oral glucose tolerance test (OGTT), blood glucose, lipid profile, serum liver markers, antioxidants, hemoglobin and glycogen were evaluated using standard procedure. The oral administration of Forskolin and MeOHSa (600 mg/kg b.w.) for 30 days resulted in significant restoration of all these parameters supported by histopathological observations too. The results clearly suggest that the Forskolin (diterpene) possess potent antidiabetic and antihyperlipidemic activities, which may be considered as a lead molecule for therapeutic purposes, and the source of Forskolin i.e. *S. amplexicaulis* can be further exploited for pharmaceutical industries.

© 2018 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. **Introduction**

Diabetes mellitus (-a group of the metabolic disorders), is characterized by hyperglycemia, and is resulting from the defects in the secretion and action of the insulin [-a protein (hormone)] or both produced by the pancreas (Maritim et al., 2003). The global burden of the disease diabetes in the year 2017 only was approximately 425 million, which have been estimated to increase up to 629 million by 2045 (Ogurtsova et al., 2017). There have been several insulin as well as oral hypoglycemic agents which are under trade for the management of diabetes (Newman and Cragg, 2016); however, its use lead to various side effects (Kameswararao et al., 2003). Therefore, identification of natural products having antidiabetic activity with least side effects become immense importance nowadays (Newman and Cragg, 2016).

Traditional knowledge of ethnic communities is the most reliable source to know the healing properties of plant species for various ailments (Venkatachalapathi et al., 2015, 2018). Recently bioinformatics tools like ‘Prediction of Activity Spectra for Substances’ (PASS) are much helpful to find the possible medicinal uses of certain bioactive compounds of ethnobotanical significance (Filimonov et al., 2014). The information collected from the ethnic communities and the tools of bioinformatics are used to identify and select plants of medicinal importance for further scientific validation. The ‘Irula’ (-one of the oldest tribal communities of India, migrated from Africa) belongs to the Negrito race, has wide knowledge in using plants for their health care (Von, 1982; Venkatachalapathi et al., 2015, 2018). *Solena amplexicaulis* (Lam.) Gandhi (family Cucurbitaceae) is the rare sighted climber, inhabiting in the dry deciduous forests of southern India, is being used by Irula tribes of Walayar valley of the Western Ghats of Tamil Nadu, India for the management of diabetes since long back (Paulsamy and Karthika, 2014).

Diabetes is affiliated with the increased ROS (free radicals) formation of tilting the balance of oxidant/antioxidant defense system of the human body (Nazirogilu and Butterworth, 2005); as a result, there is alteration in enzymatic systems, impaired Glutathione
metabolism, lipid peroxidation and lower level of Vitamin C. In the diabetes, catalane, lipids, proteins, Glutathione, DNA damage, and superoxide dismutase are various biomarkers of oxidative stress (Asmat et al., 2016). We have previously been reported that S. amplexicaulis is rich in polyphenols with strong antioxidant activity (Karthika et al., 2012), and the bioinformatics software ‘PASS’ also predicted that the Forskolin (an isolated compound from S. amplexicaulis) have antidiabetic property.; this has prompted us for the in vivo evaluation of antidiabetic and antihyperlipidemic properties of methanolic extract of S. amplexicaulis and Forskolin (the major components of methanolic extract of S. amplexicaulis) using streptozotocin (STZ) induced diabetic rats.

2. Materials and methods

2.1. Preparation of test samples

The leaves of S. amplexicaulis were collected from Madukkarai (Coimbatore, India), and the taxonomic authentication was confirmed by comparing the reference specimen (Vide No: CPS 313) housed at Botanical Survey of India, Coimbatore. The powdered leaves (1000 g) were exhaustively extracted with methanol after de-waxing with petroleum ether using soxhlet apparatus, concentrated up to dryness using rotary evaporator, and then stored at –20 °C temperature until used in the experiments. The methanolic crude extract (MeOHSa) yield was 18.6% w/w (dry weight basis). The spectral data and also our report published earlier confirmed that the chemical structure of the isolated compound as Forskolin [(3R,4aR,5S,6S,6aS,10S,10aR,10b S)-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxy-3-vinyldecahydro-1H-benzo[f]chromen-5-yl acetate] (Karthika et al., 2016). The isolation of Forskolin was made using wet packing method of silica gel (60–120 mesh) using column chromatography (Reid and Sarker, 2012).

2.2. Experimental animals

The animal studies conducted on male wistar albino rats (150–250 g) were approved (No: 659/02/a/CPCSEA) by Institutional Animal Ethical Committee (IAEC). In order to evaluate the behavioral and toxicological effects, the acute toxicity was evaluated following Organization for Economic Cooperation and Development (OECD) guideline 423 (2001). The rats were divided into eleven groups (n = 6) each (the first group served as control, the groups 2–8 were orally treated with MeOHSa at the doses of 50, 150, 300, 500, 1000, 2000 and 3000 mg/kg body weight (b.w.) respectively, and the groups 9–11 received oral doses of 10, 50 and 100 mg/kg b.w. of Forskolin respectively). The observations were made for mortality and clinical signs up to 14 days.

2.3. Oral glucose tolerance test (OGTT)

A total number of 24 rats (assigned randomly into four equal groups) were fasted for 16 h, and then were orally treated [Group 1: 1 ml of distilled water (control), Group 2: 600 mg/kg b.w. of MeOHSa, Group 3: 10 mg/kg b.w. Forskolin, Group 4: 600 μg/kg b.w. of standard Glibenclamide (Sigma- Aldrich Chemicals, India)] followed by 5 ml/kg of 50% (w/v) glucose solution after 1 h, and then the blood glucose levels were estimated (using Accu-chek, Roche Diagnostics, USA) after 60, 120 and 240 min.

2.4. Antidiabetic effect of MeOHSa and Forskolin in type 1 diabetes induced rats

2.4.1. Induction of IDDM

The insulin dependent diabetes mellitus was induced in overnight fasted wistar albino rats by the single dose of intraperitoneal injection of Streptozotocin (Sigma- Aldrich Chemicals, India) (50 mg/ kg b.w.) (0.01 M, pH 4.5). After Streptozotocin

![Fig. 1. Effect of MeOHSa and Forskolin on OCT. Values are mean ± SEM (n = 6). *P < 0.001, significantly different from the respective control group.

| Treatment group | Body weight (g) |
|-----------------|-----------------|
| Control         | 233.3 ± 10.5    |
| Diabetic        | 183.3 ± 9.8     |
| Diabetic + MeOHSa (600 mg/kg b.w.) | 176.7 ± 12.0 |
| MeOH Sa (10 mg/kg b.w.) | 173.3 ± 13.3 |
| Glibenclamide (600 μg/kg b.w.) | 176.7 ± 10.5 |

Values are mean ± SEM (n = 6). Percent increase or decrease in body weights are given in the parenthesis.

| Treatment group | Blood glucose level (mg/dL) |
|-----------------|----------------------------|
| Control         | 83.3 ± 1.4                 |
| Diabetic control| 78.5 ± 4.2                 |
| Diabetic + MeOHSa (600 mg/kg b.w.) | 86.5 ± 3.0 |
| MeOH Sa (10 mg/kg b.w.) | 83.0 ± 2.0 |
| Glibenclamide (600 μg/kg) | 79.0 ± 2.4 |

Values are mean ± SEM (n = 6). The values given in the parenthesis indicates percentage of increase or decrease in glucose concentration over 1st day.
administration, in order to stave off the hypoglycaemic shock, the rats were given 5% (w/v) glucose orally. The massive glycosuria and hyperglycemia were noted in the rats within two days after administration of Streptozotocin. The rats with blood glucose levels above 250 mg/dl were considered diabetic, and were selected for the further study.

2.4.2. Experimental regime

The diabetic rats were divided into five groups (n = 6), and were fed orally by gastric intubation once daily for 30 days in the following manner: Group 1 (Normoglycemic, control group), Group 2 (Streptozotocin-induced diabetic rats), Group 3 (MeOHSa, 600 mg/kg b.w.), Group 4 (Forskolin, 10 mg/kg b.w.), Group 5 (Glibenclamide, 600 µg/kg b.w.). The third day of induction was designated as day 1 for extract administration in diabetic rats. The fasting blood glucose levels were monitored at the interval of 10 days of administration using glucometer elite (glucose oxidase method). All the animals were sacrificed at 30th days, the blood samples were collected. The fresh serum was collected, and stored at –20 °C until further analysis of blood. The pancreas, liver and kidney were carefully excised, and fixed in 10% Formolsaline. The body weight of animals was recorded.

| Table 3 | Effect of MeOHSa and Forskolin on various biochemical markers in STZ induced diabetic rats. |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Parameter | Treatment group | Control | Diabetic control | Diabetic + MeOHSa (600 mg/kg b.w.) | Diabetic + Forskolin (10 mg/kg b.w.) | Diabetic + Glibenclamide (600 µg/kg b.w.) |
| Haemoglobin (%) | 14.5 ± 0.4 | 6.9 ± 0.2<sup>a</sup> | 12.5 ± 0.5<sup>d</sup> | 13.3 ± 0.4<sup>d</sup> | 13.9 ± 0.3<sup>d</sup> |
| SGOT (IU/L) | 41.6 ± 2.8 | 112.3 ± 3.6<sup>a</sup> | 49.4 ± 1.5<sup>d</sup> | 44.2 ± 1.7<sup>d</sup> | 42.6 ± 4.7<sup>d</sup> |
| SGPT (IU/L) | 28.2 ± 6.4 | 102.6 ± 1.4<sup>a</sup> | 57.1 ± 5.2<sup>d</sup> | 30.6 ± 2.5<sup>d</sup> | 32.9 ± 7.5<sup>d</sup> |
| HDL (mg/dL) | 52.8 ± 8.7 | 11.4 ± 2.0<sup>a</sup> | 43.5 ± 7.6<sup>d</sup> | 51.8 ± 5.0<sup>d</sup> | 49.1 ± 0.1<sup>d</sup> |
| LDL (mg/dL) | 82.8 ± 5.6 | 231.9 ± 2.5<sup>a</sup> | 95.2 ± 4.3<sup>d</sup> | 84.5 ± 1.3<sup>d</sup> | 88.2 ± 8.7<sup>d</sup> |
| TC (mg/dL) | 156.3 ± 4.6 | 280.4 ± 1.4<sup>a</sup> | 161.6 ± 5.2<sup>d</sup> | 157.8 ± 2.7<sup>d</sup> | 159.3 ± 2.5<sup>d</sup> |
| TG (mg/dL) | 103.3 ± 1.1 | 185.7 ± 1.6<sup>a</sup> | 114.7 ± 8.1<sup>d</sup> | 107.4 ± 8.1<sup>d</sup> | 109.8 ± 5.3<sup>d</sup> |
| Glycogen (mg/g liver tissue) | 19.0 ± 1.9 | 5.2 ± 1.4<sup>a</sup> | 14.4 ± 0.9 | 18.8 ± 3.7<sup>d</sup> | 18.6 ± 0.7<sup>d</sup> |

Values are mean ± SEM (n = 6).

<sup>a</sup> P < 0.001, significantly different from the control group.
<sup>b</sup> P < 0.01, significantly different from the control group.
<sup>c</sup> P < 0.05, significantly different from the control group.
<sup>d</sup> P < 0.001, significantly different from the diabetic control group.
<sup>e</sup> P < 0.01, significantly different from the diabetic control group.
<sup>f</sup> P < 0.05, significantly different from the diabetic control group.

| Table 4 | Effect of MeOHSa and forskolin on antioxidant markers in STZ induced diabetic rats. |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Parameter | Treatment group | Control | Diabetic control | Diabetic + MeOHSa (600 mg/kg b.w.) | Diabetic + forskolin (10 mg/kg b.w.) | Diabetic + glibenclamide (600 µg/kg b.w.) |
| LPO (µ moles of malondialdehyde (MDA) formed/mg protein) | Liver | 8.4 ± 0.9 | 17.8 ± 0.7<sup>a</sup> | 10.3 ± 0.3<sup>d</sup> | 9.0 ± 0.2<sup>d</sup> | 8.9 ± 0.8<sup>d</sup> |
| | Kidney | 7.1 ± 0.4 | 16.2 ± 1.4<sup>a</sup> | 8.4 ± 1.2<sup>e</sup> | 7.9 ± 0.5<sup>d</sup> | 7.9 ± 2.1<sup>d</sup> |
| SOD (units/mg protein) | Liver | 38.4 ± 0.9 | 17.6 ± 1.3<sup>a</sup> | 28.5 ± 3.2<sup>a</sup> | 37.7 ± 0.7<sup>d</sup> | 35.8 ± 0.6<sup>d</sup> |
| | Kidney | 38.8 ± 1.9 | 15.3 ± 3.0<sup>a</sup> | 29.1 ± 1.9<sup>a</sup> | 35.5 ± 2.0<sup>d</sup> | 32.5 ± 1.1<sup>d</sup> |
| CAT (µ moles of hydrogen peroxide consumed/min/mg protein) | Liver | 62.8 ± 4.1 | 21.2 ± 0.1<sup>a</sup> | 51.2 ± 0.2<sup>d</sup> | 59.5 ± 0.3<sup>d</sup> | 60.4 ± 0.4<sup>d</sup> |
| | Kidney | 53.0 ± 3.6 | 18.5 ± 0.1<sup>a</sup> | 45.0 ± 0.2<sup>d</sup> | 52.0 ± 2.2<sup>d</sup> | 51.4 ± 0.4<sup>d</sup> |
| GPx (µ moles of reduced glutathione utilized/min/mg protein) | Liver | 3.1 ± 0.2 | 1.1 ± 0.1<sup>a</sup> | 1.9 ± 0.1<sup>b</sup> | 3.0 ± 0.3<sup>d</sup> | 2.8 ± 0.2<sup>d</sup> |
| | Kidney | 2.2 ± 0.1 | 0.9 ± 0.1<sup>a</sup> | 1.7 ± 0.1<sup>b</sup> | 2.1 ± 0.1<sup>d</sup> | 2.0 ± 0.4<sup>d</sup> |
| GST (units/mg protein) | Liver | 6.3 ± 0.2 | 2.1 ± 0.2<sup>a</sup> | 5.8 ± 0.1<sup>d</sup> | 6.2 ± 0.1<sup>d</sup> | 6.0 ± 0.2<sup>d</sup> |
| | Kidney | 5.2 ± 0.2 | 1.8 ± 0.1<sup>a</sup> | 3.9 ± 0.1<sup>d</sup> | 4.9 ± 0.1<sup>d</sup> | 4.8 ± 0.4<sup>d</sup> |
| Vitamin C (µ moles/mg protein) | Liver | 13.4 ± 0.6 | 3.9 ± 0.6<sup>a</sup> | 9.4 ± 0.3<sup>d</sup> | 10.3 ± 0.3<sup>d</sup> | 11.5 ± 1.5<sup>d</sup> |
| | Kidney | 7.3 ± 0.6 | 4.5 ± 0.2<sup>a</sup> | 6.5 ± 0.2<sup>e</sup> | 7.0 ± 0.1<sup>d</sup> | 6.9 ± 0.2<sup>d</sup> |
| GSH (µ moles/mg protein) | Liver | 40.8 ± 1.0 | 20.6 ± 2.5<sup>d</sup> | 34.7 ± 1.0<sup>d</sup> | 38.7 ± 0.5<sup>d</sup> | 36.8 ± 1.6<sup>d</sup> |
| | Kidney | 33.7 ± 3.7 | 12.9 ± 2.7<sup>d</sup> | 24.0 ± 1.0<sup>d</sup> | 31.9 ± 0.8<sup>d</sup> | 28.5 ± 0.7<sup>d</sup> |

Values are mean ± SEM (n = 6).

<sup>a</sup> P < 0.001, significantly different from the control group.
<sup>b</sup> P < 0.01, significantly different from the control group.
<sup>c</sup> P < 0.05, significantly different from the control group.
<sup>d</sup> P < 0.001, significantly different from the diabetic control group.
<sup>e</sup> P < 0.01, significantly different from the diabetic control group.
<sup>f</sup> P < 0.05, significantly different from the diabetic control group.
2.4.3. Biochemical analysis

The Serum Glutamate Oxaloacetate Transaminase (SGOT), Serum Glutamate Pyruvate Transaminase (SGPT) and the levels of High and Low Density Lipoproteins (HDL and LDL), Total Cholesterol (TC) and Triglycerides (TG) in serum were assessed in an autoanalyzer (MISPA EXCEL, India). The fresh blood samples were drawn in heparinized tube, and their total haemoglobin content was estimated (Rastogi, 2005). The hepatic glycogen level estimated following method of Sadasivam and Manickam (1996). The activities of Lipid Peroxidation (Niehuis and Samuelsson, 1968), Catalase (CAT) (Sinha, 1972), Superoxide Dismutase (SOD) (Marklund and Marklund, 1974), Glutathione-S-Transferase (GST) (Habig et al., 1974), Glutathione Peroxidase (GPx) (Rotruck et al., 1973), Reduced Glutathione (Moron et al., 1979) and Vitamin C (Omaye et al., 1979) were determined in hepatic and renal tissues.

2.4.4. Histopathological studies

The whole pancreas from each animal were fixed in 10% Formolsaline, and were cut into ultra-thin sections, stained and mounted, and the histological architecture at 10× and 40× magnification in Axiostar plus microscope (Carl Zeiss, Germany).

2.5. Statistical analysis

The results were presented as mean ± S.E.M (n = 6), one-way analysis of variance (ANOVA) were performed followed by Tukey’s multiple comparison test, with the help of Graph Pad Prism version 4.0 (Graph Pad software, San Diego, California, USA). P < 0.001 was considered as significant.

3. Results and discussion

An oral load of 2.5 gm glucose resulted in nearly two fold raise of blood glucose level in 60 min which progressively decreased towards normalcy over the period of time; however, pretreatment with MeOHSa) and Forskolin or Glibenclamide significantly lead to the blood glucose levels towards normalcy. Interestingly, the efficacy of Forskolin was lower as compared to Glibenclamide.

Fig. 2. Photomicrograph showing (a) pancreatic islet of normal untreated control group, (b) STZ-induced diabetic group, (c) diabetic + MeOHSa (600 mg/kg b.w.) treated group, (d) diabetic + Forskolin (10 mg/kg b.w.) treated group and (e) diabetic + Glibenclamide (600 μg/kg b.w.) treated group.
The hypoglycemic effect of Forskolin might be due to the enhanced glucose-mediated stimulus to release insulin; this effect produced by the elevation of CAMP which activates main signaling pathways in beta cells viz., Protein Kinase (PKA) pathway and guanine nucleotide pathway regulated by CAMP (Rios-Silva et al., 2014). Further, the administration of the MeOHSa and Forskolin significantly increases the body weight (Table 1) and decreases the blood glucose levels (Table 2). The significant climb in the level of the total haemoglobin content, the reversal of the transaminase enzyme (SGOT and SGPT) activities towards their respective normal levels, the significant restoration of the lipid profile to the normalcy, increase in the glycogen content of the liver after the administration of Forskolin (Table 3) further strengthen its antidiabetic compound to reduce hyperglycemia (Shirwaiker et al., 2005) through insulin release stimulatory effect (Vijayakumar et al., 2006) and the sensitization of insulin receptors and reactivation of glycol cycle system involved in the glycogen synthesis (Huang et al., 2000; Rotimi et al., 2014).

Diabetes is associated with the increased in the formation of free radicals, tilting the balance of antioxidant/antioxidant defense system (Nazirogilu and Butterworth, 2005). The administration of the MeOH Sa and Forskolin significantly ($P < 0.05$) improved the activities of enzymic and non-enzymic antioxidants in the diabetic rats (Table 4). In addition, the administration of Forskolin markedly ameliorated islet damage comparable with Glibenclamide (Fig. 2). The hypoglycemic effect of plants used in Mexico as antidiabetics. Arch. Med. Res. 23, 59–64.
